546 — Medtecs International Income Statement
0.000.00%
- SG$65.93m
- SG$68.55m
- $54.42m
- 46
- 55
- 58
- 55
Annual income statement for Medtecs International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 400 | 144 | 56.2 | 52.6 | 54.4 |
| Cost of Revenue | |||||
| Gross Profit | 172 | 42 | -3.34 | 6.52 | 6.92 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 264 | 126 | 86.9 | 75.6 | 66.5 |
| Operating Profit | 137 | 17.8 | -30.6 | -23 | -12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 135 | 16.9 | -30.7 | -22.5 | -23.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 132 | 16.5 | -29.3 | -22.5 | -23.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 132 | 17.3 | -28.6 | -21.1 | -22.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 132 | 17.3 | -28.6 | -21.1 | -22.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.24 | 0.032 | -0.053 | -0.038 | -0.041 |
| Dividends per Share |